Dr. Geynisman Discusses Immunotherapy in RCC
Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).
Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.
Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.